Document Detail


The role of alpha-difluoromethyl ornithine as an adjuvant to immunotherapy in mice bearing transplantable tumors.
MedLine Citation:
PMID:  7935984     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
alpha-Difluoromethyl ornithine (DFMO), an inhibitor of ornithine decarboxylase (ODC), depletes cellular polyamine levels which is significantly correlated to neoplastic transformation. DFMO was used to modulate the growth rate of Ehrlich ascites carcinoma in mice and attempts were made to use DFMO as an adjuvant to immunotherapy. The therapeutic efficacy was estimated by measurement of polyamine levels of blood and ODC activity. Significant changes were also observed in the survival of the treated groups of animals, the implications of which have been discussed.
Authors:
S R Chowdhury; S Guha; U Sen
Related Documents :
20346054 - Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulati...
2148884 - Role of t cells and tumour necrosis factor in antitumour activity and toxicity of flavo...
11703364 - Evidence of a role for cd200 in regulation of immune rejection of leukaemic tumour cell...
16293104 - One-step on-column purification and refolding of a single-chain variable fragment (scfv...
2105994 - Effects of combinations of transforming growth factor-beta 1 and tumor necrosis factor ...
17640754 - Motor discoordination of transgenic mice overexpressing a microtubule destabilizer, sta...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Neoplasma     Volume:  41     ISSN:  0028-2685     ISO Abbreviation:  Neoplasma     Publication Date:  1994  
Date Detail:
Created Date:  1994-11-17     Completed Date:  1994-11-17     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0377266     Medline TA:  Neoplasma     Country:  CZECH REPUBLIC    
Other Details:
Languages:  eng     Pagination:  159-61     Citation Subset:  IM    
Affiliation:
Department of Tumor Biology, Chittaranjan National Cancer Institute, Calcutta, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adjuvants, Immunologic / pharmacology
Animals
Carcinoma, Ehrlich Tumor / pathology,  therapy*
Cell Division / drug effects
Chemotherapy, Adjuvant
Combined Modality Therapy
Eflornithine / pharmacology*
Immunotherapy*
Male
Mice
Neoplasm Transplantation
Ornithine Decarboxylase / antagonists & inhibitors
Chemical
Reg. No./Substance:
0/Adjuvants, Immunologic; 70052-12-9/Eflornithine; EC 4.1.1.17/Ornithine Decarboxylase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  3-Aminobenzamide delays rejoining of DNA strand breaks in gamma-irradiated lymphocytes from patients...
Next Document:  Human larynx carcinoma cells resistant to cis-diamminedichloroplatinum(II): mechanisms involved in t...